Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, 155 North Nanjing Street, Heping District, Shenyang City 110001, China.
Biomed Res Int. 2018 Aug 30;2018:6172670. doi: 10.1155/2018/6172670. eCollection 2018.
The objective is to compare the differences on prognosis and the therapeutic benefits between initial and second primary colorectal cancer (pCRC).
A dataset containing 377,271 initial pCRC cases and 18,617 second pCRC cases from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) 1988-2015 was evaluated. Survival comparisons were made using the log-rank test. Cox proportional hazards models were used to assess the survival benefits.
The cancer-specific survival rate of patients with initial pCRC was significantly higher than that of patients with second pCRC (5-years survival rate: 64.85% vs. 60.22%, P<0.001). The Chi-square of stratified log rank for age at diagnosis was lower than that for primary site, pTNM stage, sex, race, histology, and grade (Chi-square=86.73). There were almost no differences on therapeutic benefits between patients with initial and second pCRC except that treatments with chemotherapy were significantly associated with longer survival rate compared with treatments without chemotherapy among stage III surgical initial and second primary left-sided colon cancers patients (HR=0.764 vs. 0.581; P for interaction =0.008).
Patients with second pCRC have worse prognosis than those with initial pCRC primarily because of older age in the former group. The results evidenced that the therapeutic benefits on the prognosis for colorectal cancer were generally similar between patients with initial and second pCRC.
比较首发和第二原发结直肠癌(pCRC)患者预后和治疗获益的差异。
评估了来自美国国家癌症研究所的监测、流行病学和最终结果(SEER)1988-2015 年的 377271 例首发 pCRC 病例和 18617 例第二原发 pCRC 病例数据集。使用对数秩检验进行生存比较。Cox 比例风险模型用于评估生存获益。
首发 pCRC 患者的癌症特异性生存率显著高于第二原发 pCRC 患者(5 年生存率:64.85%比 60.22%,P<0.001)。分层对数秩检验的卡方值小于原发部位、pTNM 分期、性别、种族、组织学和分级(卡方=86.73)。除了 III 期手术治疗的首发和第二原发左侧结肠癌患者中,化疗治疗与无化疗治疗相比,与生存率显著相关(HR=0.764 比 0.581;交互作用 P=0.008)外,首发和第二原发 pCRC 患者的治疗获益几乎没有差异。
首发和第二原发 pCRC 患者的预后差异主要是由于第二原发 pCRC 患者年龄较大。结果表明,首发和第二原发 pCRC 患者的结直肠癌预后治疗获益大致相似。